IFNA1 and COVID-19: Abnormalities in the type I IFN pathway, resulting from genetic alterations (33) or from IFN-neutralizing autoantibodies (34, , –37), clearly have a causative or amplifying role in COVID-19, plausibly, by allowing the virus to replicate unchecked during the early phases of infection, before adaptive immune defenses can be recruited.